InspireMD (NSPR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, with proxy materials delivered electronically to conserve resources and reduce costs.
Shareholders are encouraged to vote by phone, internet, or mail, with detailed instructions provided for both record and street name holders.
Record date for voting is April 10, 2026, with 46,892,979 shares outstanding as of that date.
Voting matters and shareholder proposals
Election of three Class 3 directors for three-year terms: Marvin Slosman, Raymond Cohen, and Dan Dearen.
Proposal to amend the Certificate of Incorporation to increase authorized common stock from 150,000,000 to 250,000,000 shares.
Ratification of Kesselman & Kesselman as independent auditor for 2026.
Approval to adjourn the meeting if necessary to solicit additional votes.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of six members, classified into three classes with staggered terms.
Majority of directors are independent under Nasdaq rules; all committees (audit, nominating, compensation) are composed of independent directors.
Board leadership is separated between an independent chairman and CEO.
Committees held regular meetings in 2025: audit (7), nominating (1), compensation (2).
Code of ethics, insider trading, and clawback policies are in place and disclosed.
Latest events from InspireMD
- Q2 2026 saw flat revenue, a wider net loss, and a major cost-saving workforce reduction amid going concern risks.NSPR
Q2 2026 - Endovascular stenting for carotid disease is accelerating, backed by best-in-class clinical results.NSPR
Bank of America Global Healthcare Conference 2026 - CGuard® Prime leverages clinical leadership and innovation to capture a growing carotid stenting market.NSPR
Investor presentation - Q1 revenue up 122% year-over-year; net loss widened and FDA approvals expected to drive growth.NSPR
Q1 2026 - Routine proposals allow brokers to vote uninstructed shares on key capital and auditor matters.NSPR
Proxy filing - Votes sought for director elections, share increase, auditor ratification, and meeting adjournment.NSPR
Proxy filing - Innovative stent and CMS changes accelerate a stent-first shift in carotid intervention.NSPR
25th Annual Needham Virtual Healthcare Conference - Q4 revenue up 62% to $3.1M; 2026 outlook strong with up to 65% growth and $54.2M cash.NSPR
Q4 2025 - Net loss widened on higher expenses as FDA approval for CGuard Prime is anticipated in Q3 2025.NSPR
Q1 2025